Schonfeld Strategic Advisors LLC Cel Sci Corp Transaction History

Schonfeld Strategic Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$3.09 - $5.23 $77,559 - $131,273	-25,100 Reduced 56.4%	19,400 $60,000
Q2 2022 Aug 15, 2022	SELL	$2.58 - $4.99 $94,428 - $182,634	-36,600 Reduced 45.13%	44,500 $201,000
Q1 2022 May 16, 2022	BUY	$3.93 - $7.7 $318,723 - $624,470	81,100 New	81,100 $318,000
Q4 2021 Feb 14, 2022	SELL	$7.1 - $12.82 $149,100 - $269,220	-21,000 Closed	0 $0
Q3 2021 Nov 16, 2021	SELL	$7.64 - $12.49 $170,532 - $278,789	-22,321 Reduced 51.52%	21,000 $231,000
Q2 2021 Aug 16, 2021	BUY	$8.68 - $27.49 $376,026 - $1.19 Million	43,321 New	43,321 $376,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $30.4M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.